Nicolet Bankshares Inc. Has $226,000 Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Nicolet Bankshares Inc. lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 26.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 3,380 shares of the medical equipment provider’s stock after selling 1,230 shares during the period. Nicolet Bankshares Inc.’s holdings in Hologic were worth $226,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. IndexIQ Advisors LLC grew its stake in Hologic by 3.3% in the 2nd quarter. IndexIQ Advisors LLC now owns 4,210 shares of the medical equipment provider’s stock valued at $281,000 after buying an additional 135 shares during the last quarter. CX Institutional grew its stake in Hologic by 38.1% in the 2nd quarter. CX Institutional now owns 602 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 166 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Hologic by 1.0% in the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 16,576 shares of the medical equipment provider’s stock valued at $1,232,000 after buying an additional 170 shares during the last quarter. Lido Advisors LLC grew its stake in Hologic by 3.5% in the 1st quarter. Lido Advisors LLC now owns 5,086 shares of the medical equipment provider’s stock valued at $378,000 after buying an additional 170 shares during the last quarter. Finally, Rockefeller Capital Management L.P. grew its stake in Hologic by 2.0% in the 1st quarter. Rockefeller Capital Management L.P. now owns 8,682 shares of the medical equipment provider’s stock valued at $645,000 after buying an additional 171 shares during the last quarter. Institutional investors and hedge funds own 91.84% of the company’s stock.

HOLX has been the subject of a number of recent research reports. Evercore ISI raised shares of Hologic from an “in-line” rating to an “outperform” rating and set a $78.00 price objective for the company in a report on Tuesday, July 6th. Zacks Investment Research raised shares of Hologic from a “strong sell” rating to a “hold” rating and set a $71.00 price objective for the company in a report on Tuesday, June 29th. William Blair reissued an “outperform” rating on shares of Hologic in a report on Friday, July 30th. Jefferies Financial Group initiated coverage on shares of Hologic in a report on Thursday, July 29th. They issued a “buy” rating and a $95.00 price objective for the company. Finally, Morgan Stanley cut their price objective on shares of Hologic from $77.00 to $75.00 and set an “equal weight” rating for the company in a report on Friday, July 30th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $85.50.

Shares of Hologic stock opened at $76.73 on Tuesday. The company has a 50 day moving average of $75.91 and a 200-day moving average of $70.89. Hologic, Inc. has a 1-year low of $60.10 and a 1-year high of $85.00. The company has a current ratio of 1.65, a quick ratio of 1.31 and a debt-to-equity ratio of 0.69. The company has a market cap of $19.45 billion, a PE ratio of 9.84, a price-to-earnings-growth ratio of 0.69 and a beta of 1.17.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 28th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.12 by $0.21. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a net margin of 35.98% and a return on equity of 67.74%. During the same period in the prior year, the company earned $0.75 EPS. Research analysts forecast that Hologic, Inc. will post 7.76 earnings per share for the current year.

Hologic Profile

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

Read More: Average Daily Trade Volume – ADTV

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.